RIMS1 and cancer: Novel NFIB fusion partners identified in that study included MYBL1, MAP3K5, RPS6KA2, MYO6, and RIMS1.[22] It was also found that fusion transcript-specific RT-PCR for MYB-NFIB and MYBL1-NFIB and ordinary split FISH assays for MYB and MYBL1 were less sensitive.[23] In addition, KRAS and KDM6A mutations, were detected respectively in 2 patients with BG-ACC, in whom 160 cancer-related genes were analyzed using targeted genetic sequencing.